Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast … Read more
Blueprint Medicines Corp (BPMC) - Total Liabilities
Latest total liabilities as of March 2025: $853.47 Million USD
Based on the latest financial reports, Blueprint Medicines Corp (BPMC) has total liabilities worth $853.47 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Blueprint Medicines Corp - Total Liabilities Trend (2013–2024)
This chart illustrates how Blueprint Medicines Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Blueprint Medicines Corp Competitors by Total Liabilities
The table below lists competitors of Blueprint Medicines Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UGI Corporation
NYSE:UGI
|
USA | $10.80 Billion |
|
BAWAG Group AG
PINK:BWAGF
|
USA | $68.05 Billion |
|
Doosan
KO:000150
|
Korea | ₩20.11 Trillion |
|
Toppan Inc
PINK:TONPF
|
USA | $1.05 Trillion |
|
TFI International Inc
NYSE:TFII
|
USA | $4.47 Billion |
|
Valmont Industries Inc
NYSE:VMI
|
USA | $1.73 Billion |
|
Columbia Banking System Inc
NASDAQ:COLB
|
USA | $59.38 Billion |
|
Viper Energy Ut
NASDAQ:VNOM
|
USA | $2.75 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Blueprint Medicines Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Blueprint Medicines Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Blueprint Medicines Corp (2013–2024)
The table below shows the annual total liabilities of Blueprint Medicines Corp from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $881.15 Million | -4.08% |
| 2023-12-31 | $918.64 Million | +9.99% |
| 2022-12-31 | $835.23 Million | +196.72% |
| 2021-12-31 | $281.49 Million | +13.36% |
| 2020-12-31 | $248.31 Million | +2.04% |
| 2019-12-31 | $243.34 Million | +100.91% |
| 2018-12-31 | $121.11 Million | +31.98% |
| 2017-12-31 | $91.77 Million | +31.63% |
| 2016-12-31 | $69.72 Million | +99.65% |
| 2015-12-31 | $34.92 Million | +140.89% |
| 2014-12-31 | $14.50 Million | +157.43% |
| 2013-12-31 | $5.63 Million | -- |